LEADER 06413nam 2200625Ia 450 001 9910451695603321 005 20200520144314.0 010 $a1-281-79189-X 010 $a9786611791896 010 $a0-387-69057-3 024 7 $a10.1007/978-0-387-69057-5 035 $a(CKB)1000000000492339 035 $a(EBL)364191 035 $a(OCoLC)288472766 035 $a(SSID)ssj0000117286 035 $a(PQKBManifestationID)11898363 035 $a(PQKBTitleCode)TC0000117286 035 $a(PQKBWorkID)10043119 035 $a(PQKB)10708817 035 $a(DE-He213)978-0-387-69057-5 035 $a(MiAaPQ)EBC364191 035 $a(PPN)129059617 035 $a(Au-PeEL)EBL364191 035 $a(CaPaEBR)ebr10252325 035 $a(CaONFJC)MIL179189 035 $a(EXLCZ)991000000000492339 100 $a20080503d2008 uy 0 101 0 $aeng 135 $aur|n|---||||| 181 $ctxt 182 $cc 183 $acr 200 04$aThe cancer degradome$b[electronic resource] $eproteases and cancer biology /$fedited by Dylan Edwards ... [et al.] 205 $a1st ed. 2008. 210 $aNew York $cSpringer$dc2008 215 $a1 online resource (946 p.) 300 $aDescription based upon print version of record. 311 $a0-387-69056-5 320 $aIncludes bibliographical references and index. 327 $aThe Degradome and Its Analysis -- Protease Genomics and the Cancer Degradome -- The CLIP-CHIP?: A Focused Oligonucleotide Microarray Platform for Transcriptome Analysis of the Complete Human and Murine Cancer Degradomes -- The Hu/Mu ProtIn Chip: A Custom Dual-Species Oligonucleotide Microarray for Profiling Degradome Gene Expression in Tumors and Their Microenvironment -- Quantitative Real-Time PCR Analysis of Degradome Gene Expression -- Identification of Protease Substrates by Mass Spectrometry Approaches-1 -- Identification of Protease Substrates by Mass Spectrometry Approaches-2 -- Activity-Based Imaging and Biochemical Profiling Tools for Analysis of the Cancer Degradome -- Images of Cleavage: Tumor Proteases in Action -- Insights into Protease Function -- Proteolytic Pathways: Intersecting Cascades in Cancer Development -- Physiological Functions of Plasminogen Activation: Effects of Gene Deficiencies in Humans and Mice -- The Plasminogen Activation System in Tissue Remodeling and Cancer Invasion -- The Urokinase Plasminogen Activator Receptor as a Target for Cancer Therapy -- The Endocytic Collagen Receptor, uPARAP/Endo180, in Cancer Invasion and Tissue Remodeling -- Physiological and Pathological Functions of Type II Transmembrane Serine Proteases: Lessons from Transgenic Mouse Models and Human Disease-Associated Mutations -- Roles of Cysteine Proteases in Tumor Progression: Analysis of Cysteine Cathepsin Knockout Mice in Cancer Models -- In Vitro and In Vivo Models of Angiogenesis to Dissect MMP Functions -- The Surface Transplantation Model to Study the Tumor?Host Interface -- Unravelling the Roles of Proteinases in Cell Migration In Vitro and In Vivo -- New Insights into MMP function in Adipogenesis -- TIMPs: Extracellular Modifiers in Cancer Development -- The Interface Between Proteolysis and Cell Signalling -- Invadopodia: Interface for Invasion -- uPAR and Proteases in Mobilization of Hematopoietic Stem Cells -- The Urokinase Receptor and Integrins Constitute a Cell Migration Signalosome -- Measuring uPAR Dynamics in Live Cells -- Janus-Faced Effects of Broad-Spectrum and Specific MMP Inhibition on Metastasis -- Cytokine Substrates: MMP Regulation of Inflammatory Signaling Molecules -- Matrix Metalloproteinases as Key Regulators of Tumor?Bone Interaction -- The Degradome as Source of Cancer Diagnostic and Markers -- The Plasminogen Activation System as a Source of Prognostic Markers in Cancer -- Cysteine Cathepsins and Cystatins as Cancer Biomarkers -- Novel Degradome Markers in Breast Cancer -- Meta-Analysis of Gene Expression Microarray Data: Degradome Genes in Healthy and Cancer Tissues -- Degradome Gene Polymorphisms -- TIMP-1 as a Prognostic Marker in Colorectal Cancer -- Novel Therapeutic Strategies -- Structure and Inhibition of the Urokinase-Type Plasminogen Activator Receptor -- Engineered Antagonists of uPA and PAI-1 -- MMP Inhibitor Clinical Trials ? The Past, Present, and Future -- Tailoring TIMPs for Selective Metalloproteinase Inhibition -- Third-Generation MMP Inhibitors: Recent Advances in the Development of Highly Selective Inhibitors -- Protease-Activated Delivery and Imaging Systems -- Development of Tumour-Selective and Endoprotease-Activated Anticancer Therapeutics -- Targeting Degradome Genes via Engineered Viral Vectors. 330 $aProteases that act in the extracellular environment have been historically associated with tumorigenesis and metastasis by virtue of their ability to carry out "path-clearing" for cancer cells. In the past few years it has become clear that they also shape the pericellular signaling environment, with profound consequences for cell fate and phenotype in both normal development and disease states. The repertoire of proteases that cells and tissues coordinately regulate in order to modulate their local environment is the DEGRADOME ? which in humans is represented by at least 569 proteases in five catalytic classes. "The Cancer Degradome: Proteases in Cancer Biology" , edited by Dylan Edwards, Francesco Blasi, Gunilla-Høyer-Hansen and Bonnie Sloane, covers recent knowledge of the composition of the Degradome, how it can be studied using modern approaches such as transcriptomics and mass spectrometry; how protease activity can be imaged both in vitro and in vivo; how gene knockout mice have improved our knowledge of the roles of proteases in cancer; the links that have emerged between proteolysis and cell signaling; how the Degradome can be a useful source of diagnostic and prognostic markers; and finally new approaches to target proteolysis for therapy. 606 $aCancer$xMolecular aspects 606 $aProteolytic enzymes 608 $aElectronic books. 615 0$aCancer$xMolecular aspects. 615 0$aProteolytic enzymes. 676 $a616.994 701 $aEdwards$b Dylan R$01000116 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910451695603321 996 $aThe cancer degradome$92295694 997 $aUNINA LEADER 02275nam 2200553 450 001 9910810671903321 005 20240131164558.0 010 $a1-4438-8738-2 035 $a(CKB)3710000000570234 035 $a(EBL)4535042 035 $a(MiAaPQ)EBC4535042 035 $a(Au-PeEL)EBL4535042 035 $a(CaPaEBR)ebr11216046 035 $a(CaONFJC)MIL888159 035 $a(OCoLC)951223750 035 $a(OCoLC)971082982 035 $a(FINmELB)ELB148870 035 $a(EXLCZ)993710000000570234 100 $a20160622h20162016 uy 0 101 0 $aeng 135 $aurcnu|||||||| 181 $2rdacontent 182 $2rdamedia 183 $2rdacarrier 200 00$aCurating differently $efeminisms, exhibitions and curatorial spaces /$fedited by Jessica Sjo?holm Skrubbe 210 1$aNewcastle upon Tyne, England :$cCambridge Scholars Publishing,$d2016. 210 4$d©2016 215 $a1 online resource (191 p.) 300 $aDescription based upon print version of record. 311 $a1-4438-8577-0 320 $aIncludes bibliographical references and index. 330 $aExhibitionary spaces and curatorial strategies ideologically frame the encounter between art and its publics. For more than forty years, feminist art curating, as a practice of art interpretation and a politics of display, has intersected with the diverse area of feminist art historical research and feminist artistic practices. It is only recently, however, that a theorization of feminist art curating and feminist exhibition histories as a specific field of knowledge has emerged.Curating Differently is a collection of essays that offers critical perspectives on, and analyses of, the intersecti 606 $aArt$xExhibition techniques 606 $aArt$xExhibition techniques$xSocial aspects 606 $aFeminism in art 606 $aCuratorship 615 0$aArt$xExhibition techniques. 615 0$aArt$xExhibition techniques$xSocial aspects. 615 0$aFeminism in art. 615 0$aCuratorship. 676 $a707.5 702 $aSjo?holm$b Jessica 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910810671903321 996 $aCurating differently$93955317 997 $aUNINA